BioLife Solutions, Inc. (BLFS)
BioLife Solutions, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Bothell, WA, US. The stock last traded at $34.90, up 0.23% on the session, giving a market capitalisation of $1.71B. On trailing twelve-month figures it carries a trailing P/E of 33.75, a net margin of 49.1%. Its beta of 1.90 implies it has historically moved more than the broad market.
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
BioLife Solutions, Inc. is most often compared with the following Healthcare names: